Company

About

AMT Medical

AMT Medical

Zonneoordlaan 17, Ede, Gelderland 6718, NL

AMT Medical is a clinical-stage medical device company based in Ede, Netherlands, with additional facilities in Utrecht. Founded in 2015, the company specializes in developing innovative solutions for cardiac and neurosurgical bypass procedures. Their focus is on transforming bypass surgery through minimally invasive techniques, which include off-pump heart bypass surgery that avoids stopping the heart or fully opening the chest. The company offers a Cardiac Bypass System designed for keyhole and robotic surgery, which has successfully completed First-in-Human trials and is currently undergoing CE certification in Europe. Additionally, AMT Medical has commercialized a Neurosurgical Bypass Device, recognized as a Class III medical device in the EU and U.S., and noted for its life-saving capabilities. With multiple patents protecting their technology, AMT Medical aims to set a new standard in the $15 billion coronary artery disease market, targeting cardiac and neurosurgeons with their advanced solutions.

ANT Neuro

ANT Neuro

Welbergweg 74, Hengelo, Overijssel 7556, NL

ANT Neuro is a Dutch corporation specialized in the development, marketing and sales of medical and research applications. ANT Neuro was established in 1997 as a spin-off company of The University of Twente, Enschede. It now has offices located in Hengelo, Netherlands; Berlin, Germany; London, UK; Philadelphia, USA; Melbourne, Australia; and Hong Kong, China. ANT Neuro specializes in being a single-source provider of high performance products within neuroscience research and neurodiagnostics. Applications include EEG, EMG, TMS and MEG technology.

Intravacc

Intravacc

Antonie van Leeuwenhoeklaan 9, 3721 MA

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies. As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans. Part of Utrecht Science Park Bilthoven

NecstGen

NecstGen

Sylviusweg 62, Leiden, South Holland 2333 BE, NL

The Netherlands Center for the Clinical advancement of Cell and Gene Therapies (NecstGen), situated in Leiden, comprises of a state-of-the-art facility and expert knowledge for the development, production, and commercialization of Cell and Gene Therapies. NecstGen helps academic and industrial Cell & Gene Therapy developers to enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC and regulatory affairs in a brand new 4,000 m2 development & GMP manufacturing facility. We enable the next generation of therapies by translating research programs into actionalbe health solutions for patients. Our service offering: A flexible Cell and Gene Therapy manufacturing model - Full contract manufacturing services by our expert team for Cell Therapy and Viral Vector - We manufacture Pre-clinical or toxicology study material, Phase I, Phase II clinical trial material - GMP rental for any mammalian cell-based therapy type, including Cell and Viral Vector based therapies - QC, QA, and QP services supporting our cleanroom rental - Hybrid support on a flexible basis where our team compliments yours Process and assay development for Cell Therapies and Viral Vector - Process design and optimisation - Scale-up to clinically relevant volumes - Automation and closed processes - Assay development for in-process controls, release- and potency tests - Technology transfer in and out with flexibility in-mind for the future progress of your manufacturing - Consultancy-based work to advise on decision making Talk to NecstGen today about your needs for: - Induced Pluripotent Stem Cells (iPSC) - Chimeric Antigen Receptor T-Cells (CAR-T), Tumor Infiltrating Lymphocytes (TIL) T-Cell Receptor Modified T-Cells (TCR-T) - Natural Killer (NK) Cells/CAR-NK Cells - Dendritic Cells (DC) - Mesenchymal Stromal Cells (MSC) - Lentivirus (LV) - Aden-associated virus (AAV) - Oncolytic viruses - Cleanroom rental for any mammalian cell-based therapy type

Thirona

Thirona

Toernooiveld 300, Nijmegen, 6525 EC, NL

Thirona is a global company based in Nijmegen, the Netherlands, that specializes in AI-powered medical image analysis, focusing on lung and retina images. Founded in 2014, Thirona combines medical science with artificial intelligence to deliver advanced solutions for clinical trials, treatment development, and personalized patient care. The company offers high-precision quantitative analysis of medical images, including lung quantification software that analyzes chest CT scans for lung disease detection and treatment planning. Their services also include the quantification of anatomical volumes, mapping of parenchymal disease distributions, and analysis of airway and vascular morphology. In addition to lung analysis, Thirona provides retina image analysis solutions, such as iCare RETCAD, which detects conditions like diabetic retinopathy and glaucoma. Thirona collaborates with clinical research organizations, multinational MedTech companies, and professionals in interventional pulmonology, supporting over 600 clinical sites in more than 40 countries and contributing to over 200 scientific papers.